Cleared Traditional

K153440 - PowerLoc MAX Power Injectable Infusion Set

K153440 is an FDA 510(k) clearance for PowerLoc MAX Power Injectable Infusion Set, manufactured by C.R. Bard, Inc.. The device is a Class 2 General Hospital device with product code FPA cleared through the Traditional 510(k) pathway after a 265-day FDA review.

K153440 · C.R. Bard, Inc. · General Hospital
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Aug 2016
Decision
265d
Days
Class 2
Risk

K153440 is an FDA 510(k) clearance for the PowerLoc MAX Power Injectable Infusion Set, SafeStep Huber Needle Set. Classified as Set, Administration, Intravascular (product code FPA), Class II - Special Controls.

Submitted by C.R. Bard, Inc. (Salt Lake Ciy,, US). The FDA issued a Cleared decision on August 18, 2016 after a review of 265 days - an extended review cycle.

This device falls under the General Hospital FDA review panel, regulated under 21 CFR 880.5440 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the General Hospital review framework, consistent with the majority of Class II 510(k) submissions.

View all C.R. Bard, Inc. devices

FDA 510(k) Submission Details - K153440

510(k) Number K153440 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 27, 2015
Decision Date August 18, 2016
Days to Decision 265 days
Submission Type Traditional
Review Panel General Hospital (HO)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
136d slower than avg
Panel avg: 129d · This submission: 265d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

FPA Device Classification - Class 2, Special Controls

Product Code FPA Set, Administration, Intravascular
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 880.5440
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most General Hospital devices follow this clearance model.

Regulatory Peers - FPA Set, Administration, Intravascular

All 570
Devices cleared under the same product code (FPA) and FDA review panel - the closest regulatory comparables to K153440.
Paclitaxel Sets
K160007 · Baxter Healthcare Corporation · Dec 2016
Q2 Multiport IV Administration Sets and Extension Sets, Checkmate Multiport IV Administration Sets, Q2 Extension Sets
K162304 · Quest Medical, Inc. · Dec 2016
Solution Set for Epidural Use
K161323 · Baxter Healthcare Corporation · Nov 2016
Hospira Administration Sets
K160870 · Hospira, Inc. · Jun 2016
BD FlowSmart Set, MiniMed Pro-Set
K160651 · Becton, Dickinson and Company · Apr 2016
Extension Set
K153293 · B.Braun Medical, Inc. · Apr 2016